Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Targeting mitochondrial metabolism in CML

Vignir Helgason • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Vignir Helgason, PhD, University of Glasgow, Glasgow, UK, talks on dysregulated mitochondrial metabolism in chronic myeloid leukemia (CML), commenting on the potential of mitochondrial metabolism inhibitors as a novel therapeutic strategy in CML. Although experiments in cell lines and animal models have shown that such inhibitors are effective, it is necessary to reduce the toxicity of these compounds in order to evaluate them in clinical trials. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Vignir Helgason

1:04
Combining autophagy inhibitors with TKIs in CML
Vignir Helgason • 22 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals